Efficacy of XXXX foam formulation in comparison with @entity9090 lotion in the treatment of mild-to-moderate @entity1663 : a multicenter, prospective, randomized, controlled, investigator-blinded trial.

@entity1 @entity17834 @entity9090 @entity1663 @entity11885
BACKGROUND: @entity17834 foam (BVF) is a new topical corticosteroid formulation. In @entity11885 @entity1 BVF has induced a significantly greater clinical improvement in comparison with corticosteroid lotions. No data are available to date regarding the efficacy and safety of BVF in mild-to-moderate @entity1663 ( @entity1663 ). STUDY AIM: To evaluate the efficacy, tolerability and safety of BVF treatment in @entity1 with mild-to-moderate @entity1663 . SUBJECTS AND METHODS: Sixty-one @entity1 (26 @entity1 and 35 @entity1 ; mean age 41 +/- 13 years) with mild-to-moderate @entity1663 (hair loss < 26%) were enrolled in a parallel-group, investigator-blinded trial. Subjects were assigned randomly to BVF (31 @entity1 ) or to @entity9090 lotion (BDL) (30 subjects). Both treatments were applied to the affected areas twice a day for 12 consecutive weeks. OUTCOMES: The primary study outcome was to compare the hair regrowth rate. Efficacy was evaluated at weeks 8 and 12 and at follow up (week 20), using a hair regrowth score (RGS) with a scale ranging from 0 (regrowth < 10%) to 4 (regrowth > 75%). RESULTS: Fifty-seven subjects (93%) completed the trial. At week 20, the RGS was 3.1 +/- 1.5 and 1.8 +/- 1.6 in the BVF and BDL groups, respectively (P < 0.01). A RGS > 3 was observed in 61% of @entity1 in the BVF group (19/31) in comparison with 27% (8/30) in the BDL group (P < 0.03). No serious adverse events were observed in both groups during the study. CONCLUSION: @entity17834 foam has shown to be an effective and well-tolerated treatment of mild-to-moderate @entity1663 . Further trials are warranted to evaluate the role of this new formulation in comparison or in combination with intralesional corticosterioids in @entity1663 treatment.
